TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14586603
Drug: Intensive rehabilitative
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive rehabilitative treatment for 14 days
Study: 14586603
Drug: Ordinary rehabilitative
Normalized name: ordinary salt combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary rehabilitative treatment for 14 days
Study: 11056254
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion hysterosonography (SIS)
Study: 11056254
Drug: Hysterosalpingography (HSG)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hysterosalpingography (HSG) and Saline infusion hysterosonography (SIS)
Study: 11056254
Drug: Outpatient hysteroscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient hysteroscopy (OHS) and Saline infusion hysterosonography (SIS)
Study: 8816211
Drug: Bovine surfactant
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bovine surfactant (cumulative phospholipid dose of 200 mg/kg)
Study: 8816211
Drug: Bovine surfactant
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bovine surfactant (single dose of 100 mg/kg)
Study: 1409770
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation (10 mg, 100 mg, 1000 mg, 10,000 mg EPA daily; 3 mg, 33 mg, 333 mg, 3333 mg DHA)
Study: 26327799
Drug: Pre-operative ibuprofen
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative ibuprofen 400 mg
Study: 26327799
Drug: Early post-operative
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early post-operative ibuprofen 400 mg
Study: 20854173
Drug: Directly observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly observed antiretroviral therapy (DOT)
Study: 20832196
Drug: Self-administered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered therapy (Control)
Study: 19018794
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TAC and 5-fluorouracil (5-FU)
Study: 3258429
Drug: Control (electrodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (electrodes applied daily but no stimulation)
Study: 19925045
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ramipril and Telmisartan
Study: 31759587
Drug: Whipped cream
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whipped cream
Study: 18555224
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (Endometrin 100 mg twice a day, n = 12; Endometrin 100 mg three times a day, n = 11; Crinone 8% gel 90 mg every day, n = 17)
Study: 18555224
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) progesterone (50 mg every day, n = 200)
Study: 28501869
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) progesterone
Study: 17214405
Drug: Yohimbine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (20 mg/day for 21 days)
Study: 17214405
Drug: Placebo (cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose tablets)
Study: 12766655
Drug: Parasacral approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parasacral approach with 20 ml ropivacaine, 0.75% (single bolus)
Study: 12766655
Drug: Winnie's single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Winnie's single injection approach with 20 ml ropivacaine, 0.75% (single bolus)
Study: 12766655
Drug: Winnie's double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Winnie's double injection approach with 20 ml ropivacaine, 0.75% (10 ml plus 10 ml)
Study: 8262828
Drug: Intraoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiotherapy (IORT) at a dose of 25 Gy
Study: 8262828
Drug: Intraoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiotherapy (IORT) at a dose of 20 Gy or less
Study: 8262828
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of IORT and modified total esophagectomy
Study: 3553433
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg (t.i.d.)
Study: 3553433
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg (t.i.d.)
Study: 24636210
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg daily (T-scores < -2.0)
Study: 24636210
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg daily (T-scores < -2.0)
Study: 20404221
Drug: Bosentan 250
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 250 mg daily
Study: 20404221
Drug: Sitaxsentan 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxsentan 100 mg daily
Study: 15990081
Drug: Travoprost 0.004%/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travoprost 0.004%/timolol 0.5% fixed combination (Trav/Tim)
Study: 10475291
Drug: Propofol 2‐mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2‐mg/kg bolus (i.v.)
Study: 7815223
Drug: Heparin-bonded catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded catheter
Study: 27866765
Drug: SA3Ag vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SA3Ag vaccine
Study: 27866765
Drug: SA4Ag and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SA4Ag and SA3Ag vaccines
Study: 20877395
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with 4 g of omega-3 fatty acids and 20 mg of simvastatin daily for 6 weeks
Study: 20877395
Drug: Simvastatin monotherapy
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin monotherapy of 20 mg daily for 6 weeks
Study: 19359718
Drug: Toremifen 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifen 240 mg/day
Study: 19359718
Drug: Toremifen 60
Normalized name: toremifene 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifen 60 mg/day
Study: 19359718
Drug: Letrozol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozol 2.5 mg/day
Study: 15111631
Drug: Pilocarpine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (5 mg)
Study: 7492129
Drug: 5% doxepin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% doxepin cream
Study: 2049230
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (SK) infused over 60 min at a dosage of 1.5 x 10(6) i.u.
Study: 2049230
Drug: Anistreplase infused
Normalized name: Anistreplase
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anistreplase infused over 5 min at a dosage of 30 units
Study: 6791393
Drug: Hypocaloric nutrition
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric nutrition (2 g CH/kg b.w.)
Study: 6791393
Drug: Basic nutrition
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic nutrition (5 g CH/kg b.w.)
Study: 6791393
Drug: Sole AA-substitution
Normalized name: English sole
DrugBank: English sole (DB10904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sole AA-substitution (1 g AA/kg b.w.)
Study: 31713753
Drug: Anodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal tDCS combined with conventional swallowing therapy
Study: 31713753
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS combined with conventional swallowing therapy
Study: 30625179
Drug: Energy Drink
Normalized name: Boost Energy Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy Drink (250 ml containing 80 mg caffeine)
Study: 15939243
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) therapy
Study: 22284563
Drug: Early ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Early ibuprofen treatment (n = 54)
Study: 17620075
Drug: Grazax (75,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazax (75,000 SQ-T, sublingual immunotherapy tablet)
Study: 15790610
Drug: B-group vitamins
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-group vitamins (vitamin B1, 250 mg; vitamin B6, 250 mg; vitamin B12, 1000 microg twice daily) plus metformin (850 mg twice daily)
Study: 15790610
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (174 microg twice daily) plus metformin (850 mg twice daily)
Study: 11932303
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg pegvisomant
Study: 11932303
Drug: Longitudinal open-label
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longitudinal open-label pegvisomant treatment
Study: 9804648
Drug: Remacemide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide (up to 150 mg every 6 hours)
Study: 7752668
Drug: β-blockers (e.g.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blockers (e.g., bisoprolol)
Study: 7752668
Drug: β-blockers (post-MI)
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blockers (post-MI)
Study: 31047298
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab therapy (monthly or pro re nata)
Study: 27832073
Drug: 25 μmoles
Normalized name: Polyacrylamide (crosslinked; 2 mole percent bisacrylamide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μmoles sulforaphane daily for four weeks
Study: 27832073
Drug: 150 μmoles
Normalized name: Polyacrylamide (crosslinked; 2 mole percent bisacrylamide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 μmoles sulforaphane daily for four weeks
Study: 22050496
Drug: lornoxicam (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: lornoxicam (group L, n=32 patients)
Study: 22050496
Drug: paracetamol (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: paracetamol (group P, n=31 patients)
Study: 27165280
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg
Study: 7947240
Drug: rHuEPO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO treatment
Study: 11426506
Drug: Crossover treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover treatment (alternate medication)
Study: 9470828
Drug: PCI 36
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI 36 Gy in 18 daily fractions
Study: 9470828
Drug: PCI (most
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI (most commonly used regimens: 30 Gy in 10 fractions and 8 Gy in a single dose)
Study: 31765263
Drug: Nivolumab, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab, 3 mg/kg every 2 weeks for the first 4 cycles, then 480 mg every 4 weeks after cycle 4, administered intravenously.
Study: 20936979
Drug: Accelerated vaccination
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated vaccination schedule (vaccines at 0, 1, and 2 months)
Study: 20936979
Drug: Standard vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard vaccination schedule (vaccines at 0, 1, and 6 months)
Study: 20936979
Drug: Overall drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall drug users on accelerated schedule
Study: 20936979
Drug: Overall drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall drug users on standard schedule
Study: 18760649
Drug: 16 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 Gy boost dose after complete lumpectomy
Study: 18760649
Drug: 0 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 Gy boost dose after complete lumpectomy
Study: 18760649
Drug: 26 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26 Gy boost dose after incomplete lumpectomy
Study: 18760649
Drug: 10 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 Gy boost dose after incomplete lumpectomy
Study: 29980320
Drug: 16 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 Gy boost dose
Study: 18760649
Drug: 10 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 Gy boost dose
Study: 18760649
Drug: 0 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 Gy boost dose
Study: 29980320
Drug: 26 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26 Gy boost dose
Study: 15701299
Drug: Maintenance interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance interferon therapy
Study: 10066694
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (4 x 5 g/day)
Study: 8721127
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg buprenorphine suppository (BN)
Study: 8721127
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg buprenorphine suppository (BN) and 50 mg indomethacine suppository (IND)
Study: 8721127
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg buprenorphine suppository (BN) and 50 mg diclofenac suppository
Study: 8721127
Drug: No suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: No suppository (control group)
Study: 1867231
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and calcium antagonists
Study: 7066141
Drug: Neostigmine 2.5
Normalized name: neostigmine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 2.5 mg/70 kg
Study: 27580060
Drug: Non nucleoside
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non nucleoside reverse transcription inhibitor-based ART
Study: 17320241
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied 1% naltrexone cream for 2 weeks in the open study.
Study: 17320241
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied 1% naltrexone cream in the placebo-controlled crossover trial.
Study: 17320241
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream in the placebo-controlled crossover trial.
Study: 15227556
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Web and fax-based RDE systems
Study: 8141110
Drug: Control (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (all treatments)
Study: 23847109
Drug: Glycerol phenylbutyrate
Normalized name: Glycerol Phenylbutyrate
DrugBank: Glycerol phenylbutyrate (DB08909)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Glycerol phenylbutyrate (GPB) at 6 mL orally twice-daily
Study: 20888580
Drug: Ghrelin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin (50 μg)
Study: 18567539
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral doxycycline once per day for 14 days
Study: 18567539
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g intravenous ceftriaxone once per day for 14 days
Study: 18567539
Drug: Side effects
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side effects possibly related to treatment in doxycycline group
Study: 18567539
Drug: Side effects
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side effects possibly related to treatment in ceftriaxone group
Study: 12053584
Drug: Anti-CD80 monoclonal
Normalized name: Anti-CD80 monoclonal antibody
DrugBank: Galiximab (DB04901)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD80 monoclonal antibodies
Study: 12053584
Drug: Anti-CD86 monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CD86 monoclonal antibodies
Study: 8697157
Drug: 1.25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 g of ethanol per kilogram of body weight diluted to 15% in juice
Study: 6604940
Drug: Ketoprofen capsules
Normalized name: Ketoprofen Capsules
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen capsules
Study: 6604940
Drug: Biovail capsules
Normalized name: BiovaxID
DrugBank: Dasiprotimut-T (DB17287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biovail capsules
Study: 6604940
Drug: IBP tablets
Normalized name: IBP-1118
DrugBank: IBP-1118 (DB18461)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBP tablets
Study: 30695089
Drug: Conical interface
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conical interface (CI) implants
Study: 30695089
Drug: Flat-to-flat interface
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flat-to-flat interface (FI) implants
Study: 30695089
Drug: Platform-switched interface
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switched interface (PS) implants
Study: 28169430
Drug: Bendamustine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 80 mg/m², days 1, 2; Bortezomib 1.3 mg/m², days 1, 8, 15; Dexamethasone 20 mg, days 1, 2, 8, 9, 15, 16 every 28 days (up to 8 cycles), then maintenance 1.3 mg/m² IV bortezomib every 2 weeks
Study: 28169430
Drug: Original regimen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original regimen: Bendamustine 80 mg/m², days 1, 4; Bortezomib 1.3 mg/m², days 1, 4, 8, 11; Dexamethasone 40 mg, days 1, 2, 3, 4 on a 28-day cycle (up to 8 cycles)
Study: 12809960
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg/d
Study: 27075710
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg once daily for 7 days)
Study: 25192562
Drug: 3% concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% concentration cream composed of marjoram, black pepper, lavender, and peppermint
Study: 25192562
Drug: Unscented cream
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unscented cream
Study: 12373475
Drug: Early surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early surfactant administration
Study: 11040233
Drug: Enalaprilat (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (ACE inhibitor)
Study: 4946956
Drug: Bacteriophage preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacteriophage preparation (10^8 to 10^9 pfu/ml), given by mouth (25 ml for adults, 20 ml for children) for 3 days, with some receiving an intramuscular injection (20 ml) on the first day.
Study: 25867448
Drug: Self-system therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-system therapy (SST)
Study: 24787916
Drug: Treatment-as-usual (waitlist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (waitlist control) for seven weeks
Study: 20851726
Drug: Food liking
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food liking ratings for chocolate bar, muffin, banana, cola, cornflakes, potato chips, hot chocolate drink, and ice-cream
Study: 20851726
Drug: Familiarity ratings
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Familiarity ratings for chocolate bar, muffin, banana, cola, cornflakes, potato chips, hot chocolate drink, and ice-cream
Study: 20851726
Drug: Expected satiation
Normalized name: docosahexaenoic acid Oral Capsule [Expecta]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expected satiation (ES) ratings for chocolate bar, muffin, banana, cola, cornflakes, potato chips, hot chocolate drink, and ice-cream
Study: 15608836
Drug: Spironolactone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (50 mg orally twice a day for 6 months)
Study: 15608836
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral placebo twice a day for 6 months)
Study: 9639501
Drug: G‐CSF +
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF + epo (arm A: G‐CSF for 4 weeks followed by combination for 12 weeks; arm B: epo for 8 weeks followed by combination for 10 weeks)
Study: 9639501
Drug: Long-term maintenance
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term maintenance treatment
Study: 28213750
Drug: High EPA
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High EPA fish oil (750 mg EPA, 50 mg DHA)
Study: 28213750
Drug: Low EPA
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low EPA fish oil (150 mg EPA, 100 mg DHA)
Study: 21547610
Drug: Medication intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication intensification for hyperglycemia
Study: 21547610
Drug: Medication intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication intensification for hyperlipidemia
Study: 21547610
Drug: Medication intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication intensification for hypertension
Study: 21547610
Drug: Medication intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication intensification for any risk factor